ClinicalTrials.Veeva

Menu

Cohort Study of Heart Failure With Preserved Ejection Fraction in Chinese Han

N

Nanjing Medical University

Status

Enrolling

Conditions

Heart Failure

Treatments

Other: guideline recommended routine treatment

Study type

Observational

Funder types

Other

Identifiers

NCT05278026
ChiHFpEF-Cohort

Details and patient eligibility

About

To analyze factors contributing to the development and prognosis of heart failure with preserved ejection fraction.

Full description

Based on previous studies on development of heart failure with preserved ejection fraction (HFpEF), racial/ethnical background should be underscored when evaluating risk f actors for HFpEF incidence. As the ageing population increases sharply in China, HFpEF represents the dominant phenotype of all patients diagnosed with heart failure. In this cohort study, the investigators evaluated exposures or risk factors for HFpEF in Chinese Han patients with cardiovascular diseases (CVD). Our study may provide preventive and therapeutic targets for HFpEF in Chinese CVD patients.

Enrollment

2,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with CVD, defined as at least one diagnosis of coronary heart disease, hypertension, type 2 diabetes or cardiomyopathy. The definition of coronary heart disease was stenosis of the main coronary arteries ≥ 50% using percutaneous coronary angiography or coronary computed tomography angiography findings. The definition of hypertension was systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg or pharmacological treatment. The definition of type 2 diabetes was fasting blood glucose ≥ 7.0 mmol/L, random blood glucose ≥ 11.1 mmol/L and HbA1c > 6.5% or the or the use of hypoglycaemic medications. Cardiomyopathy was defined as the presence of cardiac insufficiency in patients with dilated cardiomyopathy suggested by percutaneous coronary angiography or coronary CT angiography use of hypoglycaemic medications.

Exclusion criteria

  • primary diagnoses of atherosclerosis (stenosis of the main coronary arteries < 50%), congenital heart diseases, arrhythmia, lung diseases, aortic dissection, peripheral vascular diseases, pericardial diseases, myocarditis, hypertrophic cardiomyopathy, heart valvular diseases, cardiophobia, costal chondritis, shock, thyroid diseases, infection or concomitant liver or renal dysfunction.

Trial design

2,000 participants in 3 patient groups

HFrEF
Description:
heart failure with reduced ejection fraction
Treatment:
Other: guideline recommended routine treatment
HFpEF
Description:
heart failure with preserved ejection fraction
Treatment:
Other: guideline recommended routine treatment
nonfailing control
Description:
patients without heart failure
Treatment:
Other: guideline recommended routine treatment

Trial contacts and locations

1

Loading...

Central trial contact

Junxia Zhang, MD; Chunlei Xia, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems